Roth Capital Upgrades Monogram Orthopaedics (NASDAQ:MGRM) to Strong-Buy

Monogram Orthopaedics (NASDAQ:MGRM) was upgraded by Roth Capital to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Separately, Roth Mkm began coverage on shares of Monogram Orthopaedics in a report on Monday. They set a “buy” rating and a $4.00 price objective for the company.

Monogram Orthopaedics Price Performance

NASDAQ MGRM opened at $2.68 on Monday. The firm has a market capitalization of $91.95 million, a price-to-earnings ratio of -5.70 and a beta of 2.01. The company’s fifty day moving average is $2.26 and its two-hundred day moving average is $2.39. Monogram Orthopaedics has a 52-week low of $1.53 and a 52-week high of $4.90.

Hedge Funds Weigh In On Monogram Orthopaedics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC bought a new position in shares of Monogram Orthopaedics during the 3rd quarter worth about $29,000. State Street Corp bought a new position in shares of Monogram Orthopaedics during the 3rd quarter worth about $62,000. Finally, Geode Capital Management LLC lifted its holdings in Monogram Orthopaedics by 1,267.4% during the 3rd quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock valued at $557,000 after purchasing an additional 194,776 shares during the last quarter. 0.45% of the stock is owned by institutional investors.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.